Nearly 6,000 clinical trials unrelated to COVID were stopped during the first five months of 2020, about twice the usual number, according to one analysis. “One lesson of COVID is that fast is possible,” says cardiologist John H. Alexander, a senior faculty member and researcher at Duke University's Clinical Research Institute. So we completely revised our protocol,” says Christina Brennan, vice president of clinical research at Northwell's Feinstein Institutes. Alexander has pushed for these kinds of updates to medical research as co-chair of the Clinical Trials Transformation Initiative, a public-private partnership aiming to improve the quality of medical research. Why, for example, do patients have to come in for separate research-related visits; why not collect research data when they come for ordinary care?